Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


SEC Opens Tysabri Investigation

This article was originally published in The Pink Sheet Daily

Executive Summary

The Securities & Exchange Commission has opened an investigation into the marketing suspension of Biogen Idec/Elan's multiple sclerosis therapy Tysabri (natalizumab)

You may also be interested in...

Biogen Idec Expects Tysabri-Related Charges Up To $100 Mil. In 2005

First quarter charges related to the withdrawn multiple sclerosis therapy totaled $36 mil. Inventory charges are expected in the second quarter as the company completes the natalizumab production cycle; idle capacity charges totaling $20 mil.-$30 mil. are likely in the latter half of the year.

Tysabri Withdrawal Prompts Biogen Idec To Suspend Financial Guidance

Company plans to issue revised guidance in May after warning investors not to rely on previous financial forecasts. Announcement coincides with news that a third diagnosis of PML was discovered in a clinical trial for Tysabri.

Tysabri Could Return In Fall; Marketing Suspended By Biogen Idec And Elan

One fatal, confirmed case of progressive multifocal leukoencephalopathy and one suspected case prompt withdrawal of multiple sclerosis product; risk/benefit ratio needs to be reestablished, companies say. Return to market would not be unprecedented, but Tysabri’s withdrawal sharpens focus on FDA's drug safety oversight.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts